Establishment of an antimicrobial stewardship strategy on the surgical NICU at Cairo University specialized pediatric hospital
| Autor: | Reem Mostafa Hassan, Dina M. Bassiouny, Mona Wassef, Aly Shalaby, Mona M.A. Halim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Operating Rooms
Imipenem medicine.medical_specialty medicine.drug_class Antibiotics Ampicillin/sulbactam Antimicrobial Stewardship 03 medical and health sciences 0302 clinical medicine Antibiotic resistance Intensive Care Units Neonatal 030225 pediatrics Humans Medicine Antimicrobial stewardship Prospective Studies Prospective cohort study business.industry Infant Newborn General Medicine Hospitals Pediatric Antibiotic misuse 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health Emergency medicine Vancomycin Egypt Surgery business medicine.drug |
| Zdroj: | Journal of Pediatric Surgery. 55:1959-1964 |
| ISSN: | 0022-3468 |
| Popis: | Purpose Antimicrobial resistance is a major concern that we are facing nowadays. This is due to antibiotic misuse and bacteria developing resistance to the commonly used antibiotics. This may lead to increased mortality and consumption of country resources. Implementation of an antimicrobial stewardship program [ASP] can limit the use of unnecessary antibiotics and subsequently decrease the infection rates with better patient outcome. We aimed to control antibiotic misuse, reduce infection rate, decrease drug costs, and reduce length of hospital stay in the ICU. Methods We conducted a prospective study on the surgical neonatal ICU [SNICU] over a period of 6 months divided into pre-implementation phase, followed by an ASP phase, in which we applied the antibiotic guidelines approved by the ASP committee. Data were collected in the two phases and analyzed for demographics, compliance with guidelines, prescribed antibiotics, lab investigations, surgical site infection [SSI], length of stay and patient outcome. Results Compliance to the guidelines was encountered in 86% and SSI rate decreased to 20%. Days of Therapy (DOT) per 1000 patient days showed a significant decrease in Ampicillin Sulbactam by 296 (p = 0.024), Imipenem by 220.34 (p = 0.024) and Vancomycin by 287.34 (p = 0.048). Drug cost showed a 1185.97 EGP decrease in the ASP period compared to the pre-implementation period (p = 0.714). Average LOS decreased in the ASP period by a mean difference of 2.5 (p = 0.027). Conclusion ASP implementation can control antibiotic misuse, decrease the medical care expenses and improve patient outcome. Type of study Clinical research paper. Level of evidence Level one. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect